
11 - 50 employees
💊 Pharmaceuticals
🧬 Biotechnology
Pharmaceuticals • Biotechnology
Egetis is an innovative, integrated pharmaceutical company focused on late-stage development and commercialization of treatments for serious diseases with significant unmet medical needs, particularly in the orphan drug segment. The company's lead product candidate is Emcitate (tiratricol) for MCT8 deficiency/Allan‑Herndon‑Dudley syndrome; its pipeline also includes Aladote for acetaminophen (paracetamol) overdose. Headquartered in Stockholm, Sweden, Egetis positions itself around development, regulatory interaction and market access for rare-disease therapeutics.
Selected: 🆕 Date Added.
🔥 2 hours ago
Clinical development director leading medical oversight and study strategy for Egetis Therapeutics’ rare-disease drug programs. Guiding safety, data interpretation, regulatory documentation, and cross-functional trial execution.
🕒 September 5
Field-based Regional Medical Director advancing Egetis Therapeutics’ rare-disease therapy launches. Leading scientific exchange, clinical-trial support, and pediatric specialist engagement.